Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020)
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Microbiology"
DOI: 10.1128/jcm.02449-21
Abstract: Rezafungin is a new echinocandin under development for the treatment of candidemia and invasive candidiasis. CLSI recently approved provisional susceptible-only breakpoints and epidemiological cutoff values for Candida spp. and rezafungin. The activities of rezafungin and… read more here.
Keywords: 100 susceptible; susceptible candida; candida; mic50 mic90 ... See more keywords